Bruce Huebner has joined Vermillion's board of directors.
Huebner is a managing director at LynxCom Partners. He previously was president of Osmetech Molecular Diagnostics, president and chief operating officer of Nanogen, president and CEO of TrovaGene, and executive vice president and COO of Gen-Probe.
Huebner also held sales and marketing positions at Quidel, Hybritech, and Roche Diagnostics.
Stacey Sias has left Celera, where she served as senior vice president of business development and strategic planning and as an executive director. The company disclosed Sias's departure in a recent filing with the US Securities and Exchange Commission.
Sias previously was vice president of licensing at Roche Molecular Systems and a molecular biologist at Codon and Genentech. She is a registered patent agent with the US Patent and Trademark Office.
Cristopher McReynolds has been named vice president of business development at point-of-care testing developer Alverix. He previously was CEO of Satoris. Before that, McReynolds was VP of business development for Affymetrix's molecular diagnostics business unit, and prior to that held the same role at Cepheid.
Exosome Diagnostics, a developer of biofluid-based molecular diagnostic tests for use in personalized medicine, has appointed Bob Carter, Carlos Cordon-Cardo, Keith Flaherty, and John Quackenbush to its scientific advisory board.
Carter is professor and chief of neurosurgery at the University of California, San Diego, Medical Center where he co-leads the clinical brain tumor program.
Cordon-Cardo is vice chairman of pathology and professor of pathology and urology at Columbia University as well as associate director of infrastructure at the Herbert Irving Comprehensive Cancer Center.
Flaherty is director of developmental therapeutics at the Massachusetts General Hospital Cancer Center and a lecturer in the department of medicine at Harvard Medical School.
Quackenbush is professor of computational biology and bioinformatics at the Dana-Faber Cancer Institute.